Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Colorectal Cancer: early-phase trial registry
162 of 394 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #14 of 28,707 conditions by registered trial count.
394 US clinical trials · 162 currently recruiting · #14 of 28,707 conditions by registered trial count
Colorectal Cancer: 394 US clinical trials tracked, 162 recruiting.
Colorectal Cancer is the subject of 394 registered US clinical trials on ClinicalTrials.gov, 162 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 201 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.
Enrollment posture brief
Registry condition colorectal-cancer
OPEN 162 | RECR 41% | LATE 13 | EARLY 201 | RANK #14 | SPON 22
Volume-matched condition peers
Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)
Colorectal Cancer lists 162 open slots (41% of 394 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Colorectal Cancer is recruiting above its size-band peers.
162 of 394 indexed trials (41.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Colorectal Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 22 of 394 trials (5.6%). 222 distinct sponsors appear on at least one study for this condition label.
-
Typical Colorectal Cancer enrolment sits around 132 participants.
Median target enrolment is 132 among the 382 trials that report a genuine target (sentinel values excluded). 162 of those (42.4%) plan for fewer than 100 participants.
-
Colorectal Cancer research is mostly interventional.
323 interventional and 71 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
394 total, page 2 of 8
Precise Oncology Interventions in Nutrition and Training (OnPoint)
University of Miami
NCT06534918
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals
NCT04585750
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
Wake Forest University Health Sciences
NCT03998202
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Tempus AI
NCT05234177
Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
University of California, Davis
NCT06101277
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem
NCT07020221
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Bicara Therapeutics
NCT04429542
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT07227636
A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors
Pfizer
NCT07318805
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Duke University
NCT06371768
Safety and Effectiveness Evaluation of the COLO-BT as an Alternative Treatment to the Ileostomy
JSR Medical Co.
NCT05826743
Time-restricted Eating Versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers
University of Illinois at Chicago
NCT05114798
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
A2 Biotherapeutics
NCT06682793
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
Udai Kammula
NCT03935893
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
Washington University School of Medicine
NCT06910670
The Care Tracker Study: Using Patient-Reported Data to Address Racial Disparity in Cancer Treatment
UNC Lineberger Comprehensive Cancer Center
NCT06096623
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
University of Illinois at Chicago
NCT04753359
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Merck Sharp & Dohme
NCT06428409
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics
NCT04421820
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
Ipsen
NCT06305247
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
NCT05787587
Tumor-Derived FGF19
University of Central Florida
NCT06068257
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
National Cancer Institute (NCI)
NCT06253520
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Sutro Biopharma
NCT07227168
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
EMD Serono Research & Development Institute
NCT05464030
Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer
City of Hope Medical Center
NCT07226115
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
A2 Biotherapeutics
NCT04981119
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Walnuts and Colon Health
UConn Health
NCT05195970
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics
NCT07300150
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Alentis Therapeutics
NCT07169734
Reducing Metabolic Dysregulation in Dyads
University of South Carolina
NCT06117241
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
Reema A. Patel
NCT05391126
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Innovent Biologics (Suzhou) Co.
NCT06281678
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
Cedars-Sinai Medical Center
NCT04722341
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
ALX Oncology
NCT07085091
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Novartis Pharmaceuticals
NCT06562192
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Memorial Sloan Kettering Cancer Center
NCT05568420
Telehealth Intervention for Ostomy Self-Management
City of Hope Medical Center
NCT06528990
A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors
Qurgen
NCT05989724
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
MBrace Therapeutics
NCT07145255
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
Ono Pharmaceutical Co.
NCT06948448
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
AbbVie
NCT07023289
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors
TiumBio Co.
NCT05784688
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
NGM Biopharmaceuticals
NCT07033026
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Chimeric Therapeutics
NCT06055439
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies
NCT06047379
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06974110
A Study of Mental Health Care in People With Cancer
Memorial Sloan Kettering Cancer Center
NCT06037954
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma
NCT06362369
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 132 |
| Phase 2 | 69 |
| Phase 3 | 10 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Colorectal Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Colorectal Cancer page
394 registered trials, 162 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 162 Colorectal Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Colorectal Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer condition card totals 394 registered trials; most-linked intervention Cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.